Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSA-3A Vaccine in Recurrent Prostate Cancer
NCT00109811Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2005
- Primary completion
- Sep 2007
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PSA:154-163(155L) peptide in prostate cancer (PCa), sponsored by National Cancer Institute. Started Mar 2005; status: completed.
02
Drugs
PSA:154-163(155L) peptide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00109811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109811.